JP2020532562A5 - - Google Patents

Info

Publication number

JP2020532562A5

JP2020532562A5 JP2020512875A JP2020512875A JP2020532562A5 JP 2020532562 A5 JP2020532562 A5 JP 2020532562A5 JP 2020512875 A JP2020512875 A JP 2020512875A JP 2020512875 A JP2020512875 A JP 2020512875A JP 2020532562 A5 JP2020532562 A5 JP 2020532562A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

pharmaceutically acceptable

acceptable salt

seq

Prior art date

2018-08-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 25
• 150000001875 compounds Chemical class 0.000 claims 15
• 150000003839 salts Chemical class 0.000 claims 12
• 239000000427 antigen Substances 0.000 claims 8
• 108091007433 antigens Proteins 0.000 claims 8
• 102000036639 antigens Human genes 0.000 claims 8
• 239000012634 fragment Substances 0.000 claims 8
• 229930006000 Sucrose Natural products 0.000 claims 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
• 229920000053 polysorbate 80 Polymers 0.000 claims 4
• 229940068968 polysorbate 80 Drugs 0.000 claims 4
• 239000005720 sucrose Substances 0.000 claims 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
• 239000000825 pharmaceutical preparation Substances 0.000 claims 3
• 239000004480 active ingredient Substances 0.000 claims 2
• 239000007864 aqueous solution Substances 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 239000002736 nonionic surfactant Substances 0.000 claims 2
• 229960002621 pembrolizumab Drugs 0.000 claims 2
• 239000003381 stabilizer Substances 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 102000048362 human PDCD1 Human genes 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 230000001575 pathological effect Effects 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 125000000185 sucrose group Chemical group 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1